Your browser doesn't support javascript.
loading
SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.
Ibáñez-Molero, Sofía; van Vliet, Alex; Pozniak, Joanna; Hummelink, Karlijn; Terry, Alexandra M; Monkhorst, Kim; Sanders, Joyce; Hofland, Ingrid; Landeloos, Ewout; Van Herck, Yannick; Bechter, Oliver; Kuilman, Thomas; Zhong, Weiwei; Marine, Jean-Christophe; Wessels, Lodewyk; Peeper, Daniel S.
Affiliation
  • Ibáñez-Molero S; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands.
  • van Vliet A; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands.
  • Pozniak J; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, KU Leuven, Leuven, Belgium.
  • Hummelink K; Department of Thoracic oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Terry AM; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Monkhorst K; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands.
  • Sanders J; Current address: Genmab, Utrecht, The Netherlands.
  • Hofland I; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Landeloos E; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Van Herck Y; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Bechter O; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, KU Leuven, Leuven, Belgium.
  • Kuilman T; Department of General Medical Oncology, UZ Leuven Laboratory of Experimental Oncology, Leuven, Belgium.
  • Zhong W; Department of General Medical Oncology, UZ Leuven Laboratory of Experimental Oncology, Leuven, Belgium.
  • Marine JC; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands.
  • Wessels L; Current address: Neogene Therapeutics, Amsterdam, The Netherlands.
  • Peeper DS; Bristol Myers Squibb, Redwood city, CA, USA.
Oncoimmunology ; 11(1): 2139074, 2022.
Article in En | MEDLINE | ID: mdl-36465485
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Serpins / Drug Resistance, Neoplasm / Immune Checkpoint Inhibitors / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Oncoimmunology Year: 2022 Document type: Article Affiliation country: Netherlands Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Serpins / Drug Resistance, Neoplasm / Immune Checkpoint Inhibitors / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Oncoimmunology Year: 2022 Document type: Article Affiliation country: Netherlands Country of publication: United States